That is, medical urokinase injection, which is mainly produced by a small
number of biochemical pharmaceutical factories in China. These pharmaceutical
companies purchase semi-finished products from urokinase crude product
processing companies, and produce high-quality urokinase injections that meet
medical standards through biosynthesis technology.
However, in recent years,
the shortage of urine source collection has directly led to a decrease in the
output of urokinase boutique injection, which cannot meet the needs of the
domestic drug market and hospitals. Even some pharmaceutical factories closed
down or switched production. According to the "2013-2017 China Urokinase Market
Research Report" released by Shangpu Consulting, an authoritative data
investigation agency in China, in the past five years (2008-2013), 58% of the
national pharmaceutical companies specializing in the production of urokinase
products Due to the shortage of raw material collection and closure, 10% of the
enterprises have switched production, and only 32% of the enterprises are still
barely maintaining production, but the output is far from meeting the demand of
the domestic pharmaceutical market.
The above is the relevant content summarized by the editor of Kangyuan
Company. If you want to know more, please continue to follow us. We will
regularly update you about Human chorionic gonadotropin, Human Menopausal
Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, Hormone API
Manufacturer Related content, I hope to help you.